Analysts Predict Strong Growth for Cancer Vaccine Market: Key Biotech Stocks to Consider September 04, 2024 - Baystreet.ca Issued on behalf of BioVaxys Technology Corp. VANCOUVER – USA News Group – Back in 2022, Nature published an article titled Cancer vaccines: the immunotherapy frontier, it signaled that after several decades of development that cancer vaccines were finally showing signs of efficacy and potential to help patients. Cancer experts at Memorial Sloan Kettering Cancer Center have highlighted that there are two currently approved preventative cancer vaccines available for HPV and Hepatitis B, and four approved therapeutic cancer vaccines treating prostate cancer, bladder cancer (two), and a melanoma vaccine. Analysts at Towards Healthcare project big things in the space, with a solid CAGR of 11.44% through 2033 towards a US$30.16-billion market. Behind the scenes are several biotech companies making strides in the cancer vaccine space, including developments from BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF), BioNTech SE (NASDAQ: BNTX), CureVac N.V. (NASDAQ: CVAC), Vaxart, Inc. (NASDAQ: VXRT), and ImmunityBio, Inc. (NASDAQ: IBRX). Coming up in just a few months, BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) will be presenting a “A Novel Delivery System for Personalized Peptide & mRNA Vaccines for More Targeted Therapies” at The Personalized Cancer Vaccine Summit (formerly known as the mRNA Cancer Vaccine Summit) to be held December 3-5, 2024, in Boston, MA. The novel delivery system in question is BioVaxys’ now-flagship asset DPX™ technology, a patented immune educating platform that can package a broad range of bioactive molecules to produce targeted, long-lasting immune responses enabled by various formulated components. DPX facilitates antigen delivery to regional lymph nodes, and has been demonstrated to induce robust and durable T cell and B cell responses in pre-clinical and clinical studies for both cancer and infectious disease. Officially acquired in February, BioVaxys’s DPX platform is a novel lipid-in-oil delivery platform, that has already proven its potential across multiple cancer and infectious disease studies. Recently BioVaxys announced its plans for partnering and further development with DPX. At the Personalized Cancer Vaccine Summit in Boston this December, BioVaxys Chief Medical Officer David Berd, MD, will present new data from recent in vivo studies of DPX conducted by Pramrod K. Srivastava, Ph.D., M.D., Professor, Department of Immunology, Director, Center for Immunotherapy of Cancer and Infectious Diseases and the Carole and Ray Neag Comprehensive Cancer Center at UConn Health, University of Connecticut, and Hakimeh Ebrahimi-Nik, DVM, Ph.D., Assistant Professor, Medical Oncology, The Ohio State University Comprehensive Cancer Center. “We will be withholding detailed disclosure on potential new therapeutic roles for DPX and neoepitopes until the conference, but suffice to say, the data suggests DPX has a significant role in the delivery of tumor neoepitope vaccines that induce tumor rejection, and DPX on its own appears to have an anti-tumor capacity,” said Kenneth Kovan, President and Chief Operating Officer of BioVaxys. Another organization that has been invited at the event is BioNTech SE (NASDAQ: BNTX), which recently initiated global trials of its mRNA-based vaccine, BNT116, for the potential treatment of non-small cell lung cancer (NSCLC). The trial will be conducted across seven countries, and set to involve approximately 130 patients. “We are now entering this very exciting new era of mRNA-based immunotherapy clinical trials to investigate the treatment of lung cancer,” said Prof Siow Ming Lee, a consultant medical oncologist at University College London hospitals NHS foundation trust (UCLH), which is leading the trial in the UK. “It’s simple to deliver, and you can select specific antigens in the cancer cell, and then you target them. This technology is the next big phase of cancer treatment.” BNT116 utilizes messenger RNA (mRNA) to present common tumor markers from non-small cell lung cancer (NSCLC) to the patient’s immune system, aiming to help it recognize and combat cancer cells that express these markers. The vaccine boosts immune responses against specific targets predominantly found on cancer cells, thereby minimizing the risk of toxicity to healthy cells. CureVac N.V. (NASDAQ: CVAC) has also been invited to the event in Boston, which recently announced it had advanced its cancer vaccine candidate CVGBM to Part B of its Phase 1 study in patients with resected glioblastoma. As per the announcement, CureVac saw its first patient administered in dose-confirmation Part B of the Phase 1 study, which is expected to include up to 20 patients to generate extended data on safety, tolerability, and immunogenicity of CVGBM. "After successful completion of the dose-escalation part A of this clinical study with CVGBM, the dose expansion part B is important to confirm that we have selected the appropriate dose based on safety and immunogenicity for further studies in patients suffering from glioblastoma," said Dr. Myriam Mendila, Chief Scientific Officer of CureVac. "Importantly, the review by the Data Safety Monitoring Board confirmed there have been no dose-limiting toxicities to date in Part A with the four doses tested, and have enabled us to move forward to this next part of the study." While there are already approved vaccines available that target the prevention of HPV (plays a causative role in most cases of cervical dysplasia, which leads to cervical cancers if left untreated), clinical-stage biotech company Vaxart, Inc. (NASDAQ: VXRT) is working to improve upon the available options. Recently, Vaxart announced the publication preclinical data demonstrating the potential of its mucosal vaccine technology platform in enabling therapeutic vaccination against HPV-related cervical dysplasia. While already-established prophylactic HPV vaccines are highly effective if administered prior to infection; they have not demonstrated a therapeutic effect on established infections. “The preclinical data published in Vaccines demonstrate that our mucosal vaccines stimulate T cells to destroy HPV-expressing cells, reducing the size of HPV-derived tumors and increasing the survival of mice bearing these tumors,” said Dr. Sean Tucker, Founder and Chief Scientific Officer of Vaxart. “While additional studies are needed to further characterize the immune stimulating and anti-tumor activity of our HPV-vaccine, these initial findings suggest that our mucosal vaccine platform could open the door to a non-invasive approach designed to prevent the progression to cervical cancer. As our mucosal vaccine candidates can be administered easily and are stable at room temperature, they also have potential to address global inequities associated with the treatment of HPV-related cancers.” While its flagship asset ANKTIVA is an immunotherapy and not a vaccine, ImmunityBio, Inc. (NASDAQ: IBRX) recently announced a study of ANKTIVA in combination with the AdHER2DC cancer vaccine as a potential therapy to control endometrial cancer. Expected to be completed in 2026, the QUILT 502 trial is testing ImmunityBio’s N-803 (aka ANKTIVA) in combination with the cancer vaccine which targets the HER2 protein, which is elevated in 30% of endometrial cancer—which is itself a gynecological cancer with lower survival rates and limited effective post-second-line treatment. The study is sponsored by the National Cancer Institute (NCI) which is part of the National Institutes of Health (NIH). "We are pleased to partner with the NCI on this important cancer control study involving ANKTIVA, which has demonstrated in clinical trials that activation of memory T cells may help deliver long-duration response well beyond that of checkpoint inhibitors alone," said Patrick Soon-Shiong, M.D., Executive Chairman and Global Chief Scientific and Medical Officer at ImmunityBio. "We are hopeful that the AdHER2DC investigational vaccine plus ANKTIVA will ‘rescue’ the checkpoint inhibitor pembrolizumab and kinase inhibitor lenvatinib and lead to an improved response compared with the current standard of care in this high risk population." Article Source: https://biotech-insider.com/the-phoenix-of-biotech-how-a-6m-junior-just-swooped-into-a-potential-billion-dollar-opportunity/ CONTACT: USA NEWS GROUP [email protected] (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for BioVaxys Technology Corp. advertising and digital media from the company directly. There may be 3rd parties who may have shares of BioVaxys Technology Corp., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of BioVaxys Technology Corp. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of BioVaxys Technology Corp.at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by BioVaxys Technology Corp.; this is a paid advertisement, we currently own shares of BioVaxys Technology Corp. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Analysts Predict Strong Growth for Cancer Vaccine Market: Key Biotech Stocks to Consider September 04, 2024 - Baystreet.ca Issued on behalf of BioVaxys Technology Corp. VANCOUVER – USA News Group – Back in 2022, Nature published an article titled Cancer vaccines: the immunotherapy frontier, it signaled that after several decades of development that cancer vaccines were finally showing signs of efficacy and potential to help patients. Cancer experts at Memorial Sloan Kettering Cancer Center have highlighted that there are two currently approved preventative cancer vaccines available for HPV and Hepatitis B, and four approved therapeutic cancer vaccines treating prostate cancer, bladder cancer (two), and a melanoma vaccine. Analysts at Towards Healthcare project big things in the space, with a solid CAGR of 11.44% through 2033 towards a US$30.16-billion market. Behind the scenes are several biotech companies making strides in the cancer vaccine space, including developments from BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF), BioNTech SE (NASDAQ: BNTX), CureVac N.V. (NASDAQ: CVAC), Vaxart, Inc. (NASDAQ: VXRT), and ImmunityBio, Inc. (NASDAQ: IBRX). Coming up in just a few months, BioVaxys Technology Corp. (CSE: BIOV) (OTCQB: BVAXF) will be presenting a “A Novel Delivery System for Personalized Peptide & mRNA Vaccines for More Targeted Therapies” at The Personalized Cancer Vaccine Summit (formerly known as the mRNA Cancer Vaccine Summit) to be held December 3-5, 2024, in Boston, MA. The novel delivery system in question is BioVaxys’ now-flagship asset DPX™ technology, a patented immune educating platform that can package a broad range of bioactive molecules to produce targeted, long-lasting immune responses enabled by various formulated components. DPX facilitates antigen delivery to regional lymph nodes, and has been demonstrated to induce robust and durable T cell and B cell responses in pre-clinical and clinical studies for both cancer and infectious disease. Officially acquired in February, BioVaxys’s DPX platform is a novel lipid-in-oil delivery platform, that has already proven its potential across multiple cancer and infectious disease studies. Recently BioVaxys announced its plans for partnering and further development with DPX. At the Personalized Cancer Vaccine Summit in Boston this December, BioVaxys Chief Medical Officer David Berd, MD, will present new data from recent in vivo studies of DPX conducted by Pramrod K. Srivastava, Ph.D., M.D., Professor, Department of Immunology, Director, Center for Immunotherapy of Cancer and Infectious Diseases and the Carole and Ray Neag Comprehensive Cancer Center at UConn Health, University of Connecticut, and Hakimeh Ebrahimi-Nik, DVM, Ph.D., Assistant Professor, Medical Oncology, The Ohio State University Comprehensive Cancer Center. “We will be withholding detailed disclosure on potential new therapeutic roles for DPX and neoepitopes until the conference, but suffice to say, the data suggests DPX has a significant role in the delivery of tumor neoepitope vaccines that induce tumor rejection, and DPX on its own appears to have an anti-tumor capacity,” said Kenneth Kovan, President and Chief Operating Officer of BioVaxys. Another organization that has been invited at the event is BioNTech SE (NASDAQ: BNTX), which recently initiated global trials of its mRNA-based vaccine, BNT116, for the potential treatment of non-small cell lung cancer (NSCLC). The trial will be conducted across seven countries, and set to involve approximately 130 patients. “We are now entering this very exciting new era of mRNA-based immunotherapy clinical trials to investigate the treatment of lung cancer,” said Prof Siow Ming Lee, a consultant medical oncologist at University College London hospitals NHS foundation trust (UCLH), which is leading the trial in the UK. “It’s simple to deliver, and you can select specific antigens in the cancer cell, and then you target them. This technology is the next big phase of cancer treatment.” BNT116 utilizes messenger RNA (mRNA) to present common tumor markers from non-small cell lung cancer (NSCLC) to the patient’s immune system, aiming to help it recognize and combat cancer cells that express these markers. The vaccine boosts immune responses against specific targets predominantly found on cancer cells, thereby minimizing the risk of toxicity to healthy cells. CureVac N.V. (NASDAQ: CVAC) has also been invited to the event in Boston, which recently announced it had advanced its cancer vaccine candidate CVGBM to Part B of its Phase 1 study in patients with resected glioblastoma. As per the announcement, CureVac saw its first patient administered in dose-confirmation Part B of the Phase 1 study, which is expected to include up to 20 patients to generate extended data on safety, tolerability, and immunogenicity of CVGBM. "After successful completion of the dose-escalation part A of this clinical study with CVGBM, the dose expansion part B is important to confirm that we have selected the appropriate dose based on safety and immunogenicity for further studies in patients suffering from glioblastoma," said Dr. Myriam Mendila, Chief Scientific Officer of CureVac. "Importantly, the review by the Data Safety Monitoring Board confirmed there have been no dose-limiting toxicities to date in Part A with the four doses tested, and have enabled us to move forward to this next part of the study." While there are already approved vaccines available that target the prevention of HPV (plays a causative role in most cases of cervical dysplasia, which leads to cervical cancers if left untreated), clinical-stage biotech company Vaxart, Inc. (NASDAQ: VXRT) is working to improve upon the available options. Recently, Vaxart announced the publication preclinical data demonstrating the potential of its mucosal vaccine technology platform in enabling therapeutic vaccination against HPV-related cervical dysplasia. While already-established prophylactic HPV vaccines are highly effective if administered prior to infection; they have not demonstrated a therapeutic effect on established infections. “The preclinical data published in Vaccines demonstrate that our mucosal vaccines stimulate T cells to destroy HPV-expressing cells, reducing the size of HPV-derived tumors and increasing the survival of mice bearing these tumors,” said Dr. Sean Tucker, Founder and Chief Scientific Officer of Vaxart. “While additional studies are needed to further characterize the immune stimulating and anti-tumor activity of our HPV-vaccine, these initial findings suggest that our mucosal vaccine platform could open the door to a non-invasive approach designed to prevent the progression to cervical cancer. As our mucosal vaccine candidates can be administered easily and are stable at room temperature, they also have potential to address global inequities associated with the treatment of HPV-related cancers.” While its flagship asset ANKTIVA is an immunotherapy and not a vaccine, ImmunityBio, Inc. (NASDAQ: IBRX) recently announced a study of ANKTIVA in combination with the AdHER2DC cancer vaccine as a potential therapy to control endometrial cancer. Expected to be completed in 2026, the QUILT 502 trial is testing ImmunityBio’s N-803 (aka ANKTIVA) in combination with the cancer vaccine which targets the HER2 protein, which is elevated in 30% of endometrial cancer—which is itself a gynecological cancer with lower survival rates and limited effective post-second-line treatment. The study is sponsored by the National Cancer Institute (NCI) which is part of the National Institutes of Health (NIH). "We are pleased to partner with the NCI on this important cancer control study involving ANKTIVA, which has demonstrated in clinical trials that activation of memory T cells may help deliver long-duration response well beyond that of checkpoint inhibitors alone," said Patrick Soon-Shiong, M.D., Executive Chairman and Global Chief Scientific and Medical Officer at ImmunityBio. "We are hopeful that the AdHER2DC investigational vaccine plus ANKTIVA will ‘rescue’ the checkpoint inhibitor pembrolizumab and kinase inhibitor lenvatinib and lead to an improved response compared with the current standard of care in this high risk population." Article Source: https://biotech-insider.com/the-phoenix-of-biotech-how-a-6m-junior-just-swooped-into-a-potential-billion-dollar-opportunity/ CONTACT: USA NEWS GROUP [email protected] (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for BioVaxys Technology Corp. advertising and digital media from the company directly. There may be 3rd parties who may have shares of BioVaxys Technology Corp., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of BioVaxys Technology Corp. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of BioVaxys Technology Corp.at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by BioVaxys Technology Corp.; this is a paid advertisement, we currently own shares of BioVaxys Technology Corp. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.